Barraco, Nadia
 Distribuzione geografica
Continente #
NA - Nord America 5.126
EU - Europa 2.811
AS - Asia 2.255
Continente sconosciuto - Info sul continente non disponibili 436
SA - Sud America 413
AF - Africa 71
OC - Oceania 8
Totale 11.120
Nazione #
US - Stati Uniti d'America 4.992
SG - Singapore 923
IT - Italia 847
RU - Federazione Russa 781
CN - Cina 521
DE - Germania 351
BR - Brasile 340
VN - Vietnam 214
HK - Hong Kong 202
FI - Finlandia 181
GB - Regno Unito 133
PL - Polonia 132
FR - Francia 127
CA - Canada 75
IN - India 69
BD - Bangladesh 64
JP - Giappone 60
IE - Irlanda 49
KR - Corea 47
NL - Olanda 39
SE - Svezia 31
MX - Messico 26
TR - Turchia 26
IQ - Iraq 24
ES - Italia 22
ZA - Sudafrica 22
AR - Argentina 21
AT - Austria 21
BE - Belgio 21
UA - Ucraina 19
RO - Romania 15
EC - Ecuador 13
MY - Malesia 13
IR - Iran 11
PK - Pakistan 10
VE - Venezuela 10
AL - Albania 9
EG - Egitto 8
ID - Indonesia 8
MA - Marocco 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
CO - Colombia 7
SA - Arabia Saudita 7
UY - Uruguay 7
AZ - Azerbaigian 6
CR - Costa Rica 6
KE - Kenya 6
LT - Lituania 6
PY - Paraguay 6
UZ - Uzbekistan 6
CI - Costa d'Avorio 5
JM - Giamaica 5
LB - Libano 5
PH - Filippine 5
BG - Bulgaria 4
CH - Svizzera 4
CL - Cile 4
DZ - Algeria 4
GT - Guatemala 4
HU - Ungheria 4
KZ - Kazakistan 4
NI - Nicaragua 4
NP - Nepal 4
IL - Israele 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
AO - Angola 2
BO - Bolivia 2
DK - Danimarca 2
EE - Estonia 2
EU - Europa 2
GD - Grenada 2
KG - Kirghizistan 2
MD - Moldavia 2
MO - Macao, regione amministrativa speciale della Cina 2
MQ - Martinica 2
NG - Nigeria 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
FJ - Figi 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
JO - Giordania 1
KW - Kuwait 1
KY - Cayman, isole 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
Totale 10.676
Città #
Ashburn 695
Singapore 565
Fairfield 444
San Jose 349
Chandler 315
Seattle 201
Houston 192
Hong Kong 188
Wilmington 187
Palermo 177
Woodbridge 177
Council Bluffs 161
Moscow 157
Cambridge 128
New York 118
Helsinki 116
Ann Arbor 112
The Dalles 111
Rome 103
Zgierz 102
Los Angeles 101
Munich 101
Beijing 95
Santa Clara 77
Ho Chi Minh City 71
Medford 61
Boardman 58
Hefei 56
Tokyo 56
Lauterbourg 52
Dallas 49
Des Moines 49
Chicago 48
Dublin 45
Hanoi 44
Milan 43
Frankfurt am Main 41
Princeton 40
Buffalo 39
Ludwigshafen am Rhein 35
Nanjing 35
San Diego 33
Lawrence 32
London 32
Orem 30
Seoul 30
São Paulo 29
Kitzingen 28
Altamura 27
Warsaw 26
Denver 22
Phoenix 22
Montreal 21
Bremen 20
Brussels 19
Brooklyn 17
Dearborn 17
Toronto 17
Atlanta 16
Nuremberg 16
Johannesburg 15
Chennai 14
Falls Church 13
Jinan 13
Kumar 13
Lappeenranta 13
Stockholm 13
Rio de Janeiro 12
Schiffdorf 12
Turin 12
Pune 11
Shenyang 11
Tianjin 11
Volla 11
Amsterdam 10
Baghdad 10
Boston 10
Da Nang 10
Guangzhou 10
Haiphong 10
Mexico City 10
Redwood City 10
Bari 9
Belo Horizonte 9
Catania 9
Manchester 9
Milazzo 9
Tappahannock 9
Tulsa 9
Vienna 9
Falkenstein 8
Florence 8
Hangzhou 8
Mumbai 8
Aversa 7
Bexley 7
Brasília 7
Cairo 7
Elk Grove Village 7
Izmir 7
Totale 6.648
Nome #
Dietary restriction: could it be considered as speed bump on tumor progression road? 331
E26The effects of LIPUS on ctDNA release in the medium of NSCLC cell lines 327
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 322
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 320
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 309
A headlight on liquid biopsies: a challenging tool for breast cancer management 294
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? 290
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 272
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 267
TTF-1/p63-positive poorly differentiated NSCLC: A histogenetic hypothesis from the basal reserve cell of the terminal respiratory unit 265
Nintedanib in NSCLC: Evidence to date and place in therapy 261
LncRNA H19, HOTAIR AND MALAT1 AS MOLECULAR BIOMARKERS IN GIST 260
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 250
CALR MUTATIONS IN SICILIAN ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS PATIENTS. 241
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 238
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 234
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 232
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 232
MOLECULAR ANALYSIS OF BRCA1/2 GENES AND MULTIGENE-PANEL TESTING IN SICILIAN TRIPLE NEGATIVE BREAST CANCER 229
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 218
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 212
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 212
Non-coding RNAs functioning in colorectal cancer stem cells 207
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 203
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning 198
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 186
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 181
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 180
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 180
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 178
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 175
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines 174
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups 172
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 171
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 169
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 164
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 163
HEREDITARY BREAST AND OVARIAN CANCER SYNDROME: FREQUENCY AND DISTRIBUTION OF BRCA1/2 PATHOGENIC VARIANTS IN SICILIAN POPULATION 161
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 159
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? 155
Liquid Biopsy in Gastrointestinal Stromal Tumor 150
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 148
Cancer of the Thyroid 147
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 146
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 144
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 142
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 142
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 141
Molecular tumor board 141
Current clinically validated applications of liquid biopsy 132
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses 132
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints 128
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials 113
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 112
Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code 104
Future perspectives 81
null 25
Totale 11.120
Categoria #
all - tutte 39.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.084


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022576 0 113 20 20 27 49 34 29 62 57 66 99
2022/2023912 79 143 26 133 88 128 52 92 92 12 39 28
2023/2024592 28 57 36 55 31 116 86 54 16 19 9 85
2024/20251.819 40 122 83 130 89 139 254 171 110 226 212 243
2025/20264.657 429 172 279 446 503 692 667 421 369 297 171 211
2026/2027316 210 106 0 0 0 0 0 0 0 0 0 0
Totale 11.120